#USA #Dublin #Jazz Pharmaceuticals #Epidiolex #Modeyso

Jazz Pharmaceuticals Reports Third Quarter 2025 Results

On November 5, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) published its financial results for the third quarter ending September 30, 2025. This marks a significant period for the company, showcasing a 7% increase in total revenues compared to the same quarter last year. This performance underscores the strength of Jazz's diverse portfolio, which now includes notable new product launches.

Key Financial Highlights

In Q3 2025, Jazz Pharmaceuticals reported total revenues of $1,126.1 million, up from $1,054.9 million in Q3 2024. The company’s success can largely be attributed to the impressive sales growth of several key products:

• - Epidiolex and Xywav saw double-digit growth, driving the overall increase in neuroscience revenue.
• - Additionally, the recently launched Modeyso has already contributed significantly to sales, generating $11 million in just the first quarter since its release.

CEO Renee Gala stated, "Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our team." With continued momentum, the company is well-positioned to capitalize on its product lineup, especially in the areas of sleep, epilepsy, and cancer treatments.

Recent Product Approvals

One of the most exciting developments reported was the FDA approval of Modeyso, marking it as the first targeted therapy for patients with H3 K27M-mutant diffuse midline glioma (DMG). This drug was launched commercially in August 2025, ensuring immediate access for patients in need of effective treatment options. Furthermore, the combination of Zepzelca and atezolizumab received FDA approval for first-line maintenance treatment of extensive stage small cell lung cancer (ES-SCLC), bolstering the company’s oncology portfolio.

Strikingly, Epidiolex recorded total sales of approximately $302.6 million, showcasing a remarkable 20% year-over-year increase. The growth can be attributed to increased patient demand and lower rebates in the U.S. market.

Operational Metrics

The operational success was also illustrated by the significant uptick in patient numbers:

• - Xywav continued to grow in popularity, with net sales reaching $431.4 million, reflecting an 11% increase from the previous year. This product provides relief for narcolepsy and idiopathic hypersomnia patients, with approximately 15,675 active patients reported by the end of Q3 2025.
• - Despite some products like Zepzelca experiencing a slight decline in sales due to market dynamics, overall oncology performance remains solid with revenue contributing to the company’s strong position in the pharmaceutical marketplace.

Future Outlook and Guidance

Looking ahead, Jazz Pharmaceuticals has narrowed its total revenue guidance for the year 2025 to a range of $4.175 billion to $4.275 billion from a previous range of $4.150 billion to $4.300 billion. This refined forecast reflects the company’s confidence in maintaining robust operating performance through the rest of the year, with expectations of improved sales as new products gain traction.

The outlook remains positive as Jazz anticipates sharing top-line data from the Phase 3 HERIZON-GEA-01 trial involving zanidatamab before the year-end. Dr. Ted Love has been appointed to the Board of Directors, adding further expertise to Jazz's leadership team and signaling a commitment to innovative growth and development in the biosciences sector.

In conclusion, Jazz Pharmaceuticals has made significant strides in Q3 2025 with impressive financial results, product launches, and a robust future outlook. As they continue to navigate the complexities of the pharmaceutical industry, Jazz remains persistently focused on delivering meaningful advancements that enhance patient care and shareholder value.